One-liner#

Ongoing management of dementia in primary care—optimizing cognition with cholinesterase inhibitors and memantine, managing behavioral symptoms without antipsychotics when possible, supporting caregivers, and aligning care with goals through advance care planning.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

DSM-5 Major Neurocognitive Disorder (Dementia):

1. Evidence of significant cognitive decline from previous level in one or more domains (learning/memory, language, executive function, complex attention, perceptual-motor, social cognition)
2. Cognitive deficits interfere with independence in everyday activities
3. Deficits do not occur exclusively in context of delirium
4. Deficits not better explained by another mental disorder

Staging by functional impairment:

• Mild: IADLs impaired (finances, medications, cooking, shopping); BADLs intact
• Moderate: Some BADLs impaired (dressing, bathing); needs supervision
• Severe: All BADLs impaired; dependent for all care; often nonverbal

MoCA score correlation (approximate):

• Mild dementia: MoCA 18-25
• Moderate dementia: MoCA 10-17
• Severe dementia: MoCA <10

Epidemiology#

• Prevalence: 10% of adults ≥65; 32% of adults ≥85
• Alzheimer’s disease: 60-80% of dementia cases
• Vascular dementia: 10-20% (often mixed with AD)
• Lewy body dementia: 5-10%
• Frontotemporal dementia: 5-10% (higher proportion in younger-onset)
• Risk factors: Age (strongest), family history, APOE ε4 allele, cardiovascular risk factors, low education, head trauma, hearing loss, social isolation, depression

Pathophysiology#

Mechanism (clinical understanding)#

Alzheimer’s disease:

• Amyloid-beta plaques and tau neurofibrillary tangles accumulate in brain
• Progressive neuronal loss, starting in hippocampus (memory) then spreading
• Cholinergic neuron loss → rationale for cholinesterase inhibitors
• Glutamate excitotoxicity → rationale for memantine

Vascular dementia:

• Cumulative effect of large vessel strokes, small vessel disease, or both
• White matter ischemia disrupts connections between brain regions
• Often coexists with Alzheimer’s pathology (“mixed dementia”)
• Stepwise progression typical; may stabilize with vascular risk control

Lewy body dementia:

• Alpha-synuclein deposits (Lewy bodies) in cortex and brainstem
• Overlaps with Parkinson’s disease pathology
• Fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behavior disorder
• Extreme sensitivity to antipsychotics (can cause severe parkinsonism, NMS)

Frontotemporal dementia:

• Tau or TDP-43 protein accumulation in frontal and temporal lobes
• Behavioral variant: Disinhibition, apathy, loss of empathy, compulsive behaviors
• Language variants: Progressive aphasia
• Younger onset (often 50s-60s); memory relatively preserved early

How to explain to patients#

“Dementia is caused by damage to brain cells that affects memory, thinking, and behavior. In Alzheimer’s disease, abnormal proteins build up in the brain and cause brain cells to die over time. This usually starts in the part of the brain that controls memory, which is why forgetting recent things is often the first sign. As more brain cells are affected, other abilities like language, judgment, and eventually basic functions like walking and swallowing become harder.”

“The medications we use can help the brain work better with the cells it has left, but they can’t stop the underlying damage. That’s why we also focus on keeping you safe, supporting your family, and planning ahead while you can still participate in decisions.”

Clinical presentation#

Characteristic symptoms#

By dementia type:

Behavioral and psychological symptoms of dementia (BPSD):

• Occur in 80-90% of patients at some point
• Agitation, aggression, irritability
• Apathy (most common; often mistaken for depression)
• Depression, anxiety
• Psychosis (delusions, hallucinations)
• Sleep disturbance, sundowning
• Wandering, pacing
• Disinhibition, inappropriate behavior
• Resistance to care

Physical exam findings#

• Alzheimer’s: Often normal neurologic exam early; frontal release signs late
• Vascular: May have focal deficits, gait abnormality, pseudobulbar affect
• Lewy body: Parkinsonism (bradykinesia, rigidity, shuffling gait), postural instability
• Frontotemporal: Frontal release signs; primitive reflexes; may have motor neuron signs

Red flags#

• Rapid progression (weeks to months) → Consider CJD, autoimmune encephalitis, malignancy
• New focal neurologic deficits → Stroke, mass, subdural hematoma
• Acute worsening → Delirium superimposed on dementia (infection, medication, metabolic)
• Gait + incontinence + dementia → Normal pressure hydrocephalus (potentially reversible)
• Severe antipsychotic reaction → Lewy body dementia (avoid antipsychotics)

Diagnostic workup#

Initial evaluation#

For patients with established dementia diagnosis, ongoing monitoring includes:

Confirmatory testing#

If diagnosis uncertain or atypical features:

When to refer for specialist workup#

• Young-onset dementia (<65 years)
• Rapid progression
• Atypical features (prominent hallucinations, parkinsonism, behavior change)
• Diagnostic uncertainty
• Considering disease-modifying therapy (anti-amyloid antibodies)
• Complex behavioral symptoms not responding to treatment
• Family requesting second opinion

What NOT to order#

• Routine genetic testing (APOE): Does not change management; causes anxiety; insurance implications
• Repeat imaging in stable, typical Alzheimer’s: Unlikely to change management
• Extensive lab panels in established dementia: Focus on treatable causes only if new symptoms
• Lumbar puncture routinely: Reserve for atypical cases or rapid progression

Treatment#

Goals of therapy#

Realistic expectations:

• Cholinesterase inhibitors: Modest symptomatic benefit; may slow decline by ~6 months; 50% show no measurable response
• Memantine: Modest benefit in moderate-severe; may help behavioral symptoms
• No current treatment stops or reverses progression (disease-modifying therapies emerging but limited)

Non-pharmacologic management#

Cognitive and behavioral interventions (evidence-based):

Environmental modifications:

• Adequate lighting (reduce sundowning)
• Remove clutter and tripping hazards
• Door alarms and locks (wandering prevention)
• ID bracelet with contact information
• Remove or secure firearms
• Simplify environment (reduce overstimulation)

Managing behavioral symptoms without medications (FIRST LINE):

1. Identify and treat underlying causes (pain, infection, constipation, medication side effect)
2. Identify triggers (time of day, specific activities, people, environments)
3. Modify environment (reduce noise, improve lighting, remove mirrors if causing distress)
4. Redirect and distract (don’t argue or correct; go along with reality)
5. Validate emotions (“I can see you’re upset”)
6. Ensure basic needs met (hunger, thirst, toileting, temperature)
7. Structured activities and routine

Behavioral symptom medication guide (use only when non-pharm fails):

For depression: Sertraline 25-50 mg or escitalopram 5-10 mg first-line; mirtazapine 7.5-15 mg if poor appetite. Avoid TCAs.

For anxiety: SSRI or buspirone 5-10 mg TID first-line; trazodone 25-50 mg second-line. Avoid benzodiazepines.

For agitation: Non-pharm first; citalopram 10-20 mg or trazodone; low-dose antipsychotic only if severe. Avoid benzodiazepines.

For psychosis: Non-pharm first; if severe, quetiapine 12.5-50 mg only. Avoid typical antipsychotics; avoid all antipsychotics in LBD.

For insomnia: Sleep hygiene first; trazodone 25-50 mg or melatonin 3-5 mg. Avoid benzodiazepines, Z-drugs, diphenhydramine.

Antipsychotic warnings: BLACK BOX WARNING—increased mortality in elderly with dementia (1.6-1.7x). Use only for severe symptoms threatening safety, lowest dose, shortest time. Avoid in Lewy body dementia. Reassess every 3 months.

Pharmacologic management#

Cholinesterase inhibitors (mild-moderate Alzheimer’s, Lewy body, vascular):

NMDA receptor antagonist (moderate-severe):

Combination therapy: Donepezil + memantine commonly used in moderate-severe AD; Namzaric (donepezil 10 mg + memantine ER 28 mg) available as single pill.

When to discontinue cognitive medications:

• Severe dementia with no perceived benefit
• Significant side effects (bradycardia, syncope, severe GI)
• Patient/family preference after informed discussion
• Consider gradual taper; some patients decline noticeably after stopping

Patient counseling points#

For cognitive medications: “This medication helps the brain use its remaining chemical messengers more effectively. It won’t cure the dementia or stop it from progressing, but it may help with memory and thinking for a while. About half of people notice some benefit. Common side effects include nausea, diarrhea, and vivid dreams. We’ll start with a low dose and increase gradually. If you don’t notice any benefit after several months, we can discuss whether to continue.”

For behavioral symptoms: “Behavioral changes like agitation, anxiety, and sleep problems are very common in dementia. They’re often the brain’s way of communicating distress—pain, fear, overstimulation, or unmet needs. Before using medications, we try to identify and address the underlying cause. Medications for these symptoms have significant risks in older adults with dementia, so we use them only when absolutely necessary and at the lowest effective dose.”

Monitoring and follow-up#

Patient education#

What is this condition?#

Dementia is when the brain has trouble with memory and thinking. Brain cells get damaged and stop working well. The most common type is Alzheimer’s disease.

Dementia is not normal aging. We all forget things sometimes. But dementia causes bigger problems—like forgetting how to do tasks you’ve done for years, or getting lost in places you know well.

What you can do#

• Stay active—walking and exercise help the brain
• Spend time with family and friends
• Keep your mind busy—puzzles, reading, music
• Follow the same daily routine
• Take your medicines as told
• Eat regular meals
• Get enough sleep
• Don’t drink alcohol

When to seek care#

Call your doctor if you notice:

• Sudden change in thinking (could be an infection)
• Fever, pain, or trouble breathing
• Falls or injuries
• Trouble swallowing or choking on food
• Weight loss
• Anger or upset that can’t be calmed at home
• Caregiver feeling overwhelmed

Questions to ask your doctor#

• What type of dementia do I have?
• What will happen over time?
• Are there medicines that might help?
• What can I do to stay healthy?
• How can my family get ready for the future?
• What help is out there for me and my caregivers?
• When should we talk about driving?
• What choices should I make now while I still can?

Prognosis and monitoring#

Expected course#

Average survival after diagnosis: 4-8 years for Alzheimer’s (highly variable; range 3-20 years)

Factors affecting prognosis:

• Age at diagnosis (younger = longer course)
• Dementia type (FTD often faster; vascular variable)
• Comorbidities
• Quality of care and support

Monitoring parameters#

Complications to watch for#

• Falls and fractures: Due to gait instability, medication effects, environmental hazards
• Aspiration pneumonia: Swallowing difficulty in later stages; leading cause of death
• Urinary tract infections: Incontinence, incomplete emptying, catheter use
• Pressure ulcers: Immobility in late stages
• Delirium: Superimposed on dementia; often from infection, medication, dehydration
• Caregiver burnout: Depression, health decline, elder abuse risk
• Weight loss and malnutrition: Forgetting to eat, swallowing difficulty, decreased appetite

Special populations#

Elderly/geriatric#

All dementia patients are elderly by definition of the condition’s epidemiology. Key considerations:

Medication adjustments:

• Start cholinesterase inhibitors at lowest dose; titrate slowly
• Monitor for bradycardia (especially if on beta-blockers)
• Avoid anticholinergic medications (worsen cognition)
• Avoid benzodiazepines (increase fall risk, worsen cognition)
• Simplify medication regimen; use pill boxes or supervision
• Address polypharmacy—dementia patients often on multiple medications with drug interactions

Beers Criteria medications to avoid:

• Anticholinergics (diphenhydramine, oxybutynin, TCAs)
• Benzodiazepines
• Antipsychotics (use only if severe behavioral symptoms)
• First-generation antihistamines

Chronic kidney disease#

Other populations#

Lewy body dementia:

• Cholinesterase inhibitors often MORE effective than in AD
• AVOID antipsychotics (severe sensitivity; can cause parkinsonism, NMS, death)
• If psychosis requires treatment: quetiapine only, lowest dose
• Pimavanserin (Nuplazid) FDA-approved for Parkinson’s psychosis; may help LBD

Frontotemporal dementia:

• Cholinesterase inhibitors NOT recommended (may worsen behavior)
• SSRIs for behavioral symptoms (disinhibition, compulsions)
• Trazodone for agitation, sleep
• No disease-modifying treatment

Vascular dementia:

• Cholinesterase inhibitors may have modest benefit
• PRIMARY treatment: Aggressive vascular risk factor management
• BP control, statin, antiplatelet (if ischemic), diabetes management, smoking cessation

Patients with cardiac conduction disease:

• Cholinesterase inhibitors can cause bradycardia
• Avoid if sick sinus syndrome or AV block without pacemaker
• Monitor HR; consider ECG before starting
• Use with caution if on beta-blockers or other rate-slowing agents

When to refer#

Specialist referral criteria#

Neurology/Geriatrics referral:

• Diagnostic uncertainty
• Young-onset dementia (<65)
• Atypical features (prominent hallucinations, parkinsonism, rapid progression)
• Considering disease-modifying therapy (anti-amyloid antibodies)
• Refractory behavioral symptoms
• Family request for second opinion

Psychiatry/Geriatric psychiatry referral:

• Severe behavioral symptoms not responding to first-line treatment
• Severe depression or suicidal ideation
• Complex psychosis
• Need for antipsychotic management in high-risk patient

Palliative care referral:

• Moderate-severe dementia with declining function
• Goals of care discussions needed
• Symptom management challenges
• Family support needs

Social work referral:

• Caregiver burnout or depression
• Financial concerns
• Need for community resources
• Placement decisions
• Suspected elder abuse or neglect

Urgency levels#

Smartphrase snippets#

Stable/controlled: Dementia follow-up, [type], [stage], cognitive and functional status stable. Current medications tolerated, safety reviewed. Advance directives in place, continue current regimen. Follow-up in [3-6 months].

Worsening/uncontrolled: Dementia with decline, caregiver reports [increased confusion / behavioral symptoms / functional decline]. Evaluated for delirium, no acute precipitant identified. Plan: [adjust medications / increase supervision / goals of care discussion]. Follow-up in [4-6 weeks].

New diagnosis counseling: New diagnosis of [type] dementia discussed with patient and family, explained progressive nature. Started donepezil 5 mg qHS, advance care planning initiated. Safety assessment completed, resources provided. Follow-up in 4-6 weeks.

Behavioral symptom management: Dementia with [agitation / psychosis / sleep disturbance], evaluated for underlying causes. Non-pharmacologic interventions [implemented / reinforced]. [Starting / deferring] medication given [severity / risks], follow-up in [1-2 weeks].

Related pages#

• Cognitive Decline (complaint) — Initial evaluation of memory loss and dementia workup
• Delirium (complaint) — Distinguishing acute confusion from dementia
• Polypharmacy (complaint) — Medication review and deprescribing in dementia
• Falls (complaint) — Fall prevention in cognitively impaired patients
• Failure to Thrive (complaint) — Weight loss and decline in dementia
• Frailty (problem) — Overlap between frailty and dementia syndromes
• Major Depressive Disorder (problem) — Depression in dementia vs pseudodementia